US equities |
MU $1,035.84 ▼-4.79% NVDA $230.48 ▼-2.94% SNDK $1,609.46 ▼-4.90% AMD $620.68 ▼-3.90% INTC $107.08 ▼-5.34% AAPL $340.42 ▲+1.11% META $720.89 ▼-0.06% SPCX $160.57 ▼-4.19%
FinancialContent

Articles published by Paratek Pharmaceuticals, Inc.

News headline image
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated Pathogens
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher Bostrom to Chief Financial Officer
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ZLAB
News headline image
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers PRTK